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ABSTRACT
A process for preparing bromine-containing dyes la
belled with gamma-emitting isotopes of bromine, and
the product thereof which is useful as an imaging agent

for the hepato-biliary system, particularly in dynamic
imaging methods. The dyes prepared are from the class
of triarylmethane dyes, and also from the phthalein
subclass of the class of xanthene dyes, and the labelling
thereof is effected with 76Br, 77Br or 82Br. The process
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SYNTHESIS ANDUSE OF DIAGNOSTIC

Rose Bengal-1311. This particular isotope, because of the
emission of particulate matter v(B f), is not ideally suited

RADIO-PHARMACEUTICALS COMPRISING
RADIOACTIVE ISOTOPES OF BROMINE WITH
DYES'

FIELD'OF THE INVENTION
This invention relates to a process for making bro

mine-containing dyes labelled ‘with gamma-emitting
isotopes of bromine, and the product thereof which is
useful as a diagnostic radio-pharmaceutical. More par

ticularly, the invention is concerned with the procedure
employed for synthesizing said dyes labelled with gam
ma-emitting isotopes of bromine, which involves pre
cautions for minimizing the exposure of personnel to
damaging levels of harmful radiation. Also, the inven
tion is particularly concerned with ‘the use of a diagnos

tic radiopharmaceutical product which is far superior to
presently known products employed in diagnostic nu
clear medicine as imaging agents for the hepato-biliary
system to visualize abnormalities and to determine the

function thereof by dynamic imaging.

'

for use in humans. The consequences of the use of B"

emitting radiopharmaceuticals include:
(a) The dose must be very low;
(b) Preparations which contain excessive 1311 as the
iodide can endanger the thyroidbecauseiodide is

concentrated in, this organ;
(0) The drug is cleared from the blood at a relatively
slow rate (8-10 min. half life for Rose Bengal com
pared with 1.5 min. for bromphenol blue).'
The rate of blood clearance becomes important in
considering the length of time one must wait after injec
tion prior to imaging.

'

’

‘

' There ‘is an' alternative iodine label (Iodine-123)

which like bromine-77 is cyclotron produced. This
isotope does not decay by emission of particulate mat
ter, but has a single 'y ray of 0.16 Mev. The major draw
back is that iodine-123 has a short half life (13 hours).
This limitation in half life would necessitate the in

house production of radiopharmaceuticals labelled with
iodine-123; this limits its use to facilities which are phys

THE PRIOR ART

ically close to a cyclotron. Bromine-77, however, due
Related Diagnostic Radiopharmaceutical Products Of 25 to its relatively long half life (56 hours) can be produced
at the cyclotron site, incorporated into a radiopharma
The Prior Art Which Are Useful As Imaging Agents

For The Hepato-biliary System
The drug which has been most widely used in the
diagnosis of liver malfunction and measurement of
hepato-biliary function in nuclear medicine is a radioac
tive dye, i.e., Rose Bengal in which the iodine substitu
ents are of the 1311 type. This dye is prepared in high

yield by an exchange reaction. The procedure involves
re?uxing Rose Bengal in acid form with radio-iodine
(Na"‘I and oxidizing agent) overnight to carry out an
exchange type of reaction. The radioiodinated Rose
Bengal acid is precipitated with acid, washed with wa
ter, and, by treatment with sodium hydroxide, is formu
lated as the sodium salt. This material can then be steril

ceutical, shipped anywhere vin the country, and stored
for several days before use.
‘ An alternative method for estimating hepato-biliary
function is the use of contrast agents and X-rays. In this

type of diagnostic procedure, the patient ingests a large
dose (600 mg) of drug and after 12 ‘hours undergoes
exposure to an external source of radiation. The disad
vantages of this procedure are:
'

(a) Large dose of drug; the contrast agents are known to
have speci?c toxicosis;

'

(b) The patient receives a much larger dose of radiation
(a single X-ray exposes the patient to a greater dose
than the total exposure of the radioactive dye);

(c) The diagnosing physician gets much less information
ized by autoclaving or sterile ?ltration. The product is
to work with.
"
stable when formulated with propylene glycol and
stored at refrigerated temperatures.
For example, the X-ray procedure gives one or two
Another drug suggested as a potential hepato-biliary
points in time, while the nuclear medicine technique can
imaging agent is dibromo-estrone, in which the bromine
give dynamic data involving literally thousands of data
45
substituents are 77.Br. Spicer et a1, Int. J. Appl. Rad. 2nd
points over a period of time. It should be re-emphasized
Isot, Vol. 28, pp. 163-168 (1977) have suggested that
that the radiation technique exposes the patient to a
77Br-2,4-dibromoestrone may be a tracer of potential
much higher dose of radiation for one data point than
value for liver and gallbladder function studies.
the nuclear medicine technique does for thousands of
U.S. Pat. No. 3,928,552 to Winchell et al, issued Dec.

23, 1975, is directed to a radiopharmaceutical compris

data points.’

ing Z-mercaptoisobutyric acid chelating reduced tech
netium-99m for scintigraphically imaging the liver and
biliary tract morphology and function. '

U.S. Pat. No. 3,981,980’to Baker et al, issued Sept. 21,
1976, is directed to a diagnosticsubstance for cholescin
tigraphy which is formed by the reaction of pyridoxal
and amino acids labelled with a radionuclide, in pyro
gen-free water, the reaction product being adjusted to a
pH of 8 to 9 and then autoclaved and cooled'to produce
a sterile, pyrogen-free non-antegenic solution for injec 60

tion for biliary scanning.
Comparison With Presently Employed Products Used
In Diagnosis Of Liver Function And Measurement of

Hepato-biliary Function In Nuclear Medicine
As noted above, the drug most widely used in the
diagnosis of liver malfunction and measurement of
hepato-biliary function in nuclear medicine today is

\OBJECTS

-

THE INVENTION

.An object of the present invention is to provide a

process for- producing a diagnostic radiopharmaceutical
product labelled with a radioactive halogen by a substi~
tution type of reaction not previously employed in the
prior art, and which is simpler to carry out than the

prior art processes involving exchange reactions.
Another object of the present invention is to provide
a diagnostic radiopharmaceutical product labelled with
a radioactive halogen which does not have the disad

vantages of the products previously employed in the
prior art for hepatic-biliary morphology and function
studies.
A further object of the'invention is to provide a

method for using the diagnostic radiopharmaceutical
product of the invention in. nuclear medicine tech

niques.

4,256,727
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These and other objects and advantages of the pres

TABLE I-continued

ent invention will become apparent to those skilled in
the art from a consideration of the following speci?ca

tion and claims, taken in conjunction with the accompa

Br

S

I

nying drawings.
HO

C '— 0

/O
\0

GENERAL DESCRIPTION OF THE INVENTION
CH3

The starting material is the immediate precursor of

Br

the ?nally desired dye containing no bromine. For ex

CH3
OH

ample, if the ?nally desired dye is tetrabromophenol

Bromcresol purple: 4,4'-(3H-2,1-benzoxathiol-3-ylidene)

phthalein in which the four bromine atoms are either
76Br, 77Br or “Br, then the starting material is the well

bis[2-bromo-6-methylphenol]S,S-dioxide

known phenolphthalein. The ?nally desired dye must of

Br

course be already known to be one which is excreted to
a large extent in bile in a number of animal species. The

CH3

HO

synthesis occurs through the reaction of 76Br2, 77Br2 or
82Brz in glacial acetic acid or'any other suitable inert
reaction medium with said immediate precursor of the
dye containing no bromine. The radioactive product is
recovered from the reaction mixture by evaporation of
the reaction medium containing it, separated by selec

5

'

/0

I \O

'

C — 0

CH3
Br

Br

Br

01-!

Bromcresol green: 4,4'-(3H-2,l-benzoxathiol-3-ylidene)
bis[2,6-dibromo-3-methylphenol]S,S-dioxide ‘

tive extraction, and puri?ed by column chromotogra
phy or other suitable procedure.

25

DETAILED DESCRIPTION OF THE
INVENTION
A more complete understanding of the procedures
I and products of the present invention may be had by 30

Ethyl Eosin: 2',4’,5',7',-tetrabromo?uorescein ethyl ester
Cl

reference to theaccompanying drawings in which
FIG. 1 is a schematic flow diagram of the processes

of the invention setting forth the preferred modes of
operation.

'

FIG. 2 illustrates an apparatus suitable for carrying
out the process shown in FIG. 1.

The flow diagram of FIG. 1 mentions certain speci?c

Br

reactants and procedural steps which are the most desir
able in carrying out the present invention. Other reac
tants and procedural steps can be employed, however,
as will be explained more fully in a later section of this

Br

speci?cation. For instance, although the ?ow diagram
refers speci?cally to the use of 76Br2, 77Br2 or 82Br; as

the brominating agent for the dye precursor com 45
pound,the use of other gamma-emitting isotopes of Br2
is feasible.

'

In the starting stage of this flow diagram there is
given, as an example of a suitable dye precursor com

pound, phenolphthalein. All of the dyes in the following
Table cari be prepared by the process of this invention.
They are shown in their ?nal brominated form, includ

ing tetrabromophthalein. The starting compounds are,
of course, the same as the ?nal dye compounds except
that they are not brominated in any position.
TABLE I

Tetrabromophenolphthalein: 3,3-Bis-(3,5-dibromo-4

hydroxy-phenylyl(3l-I)-isobenzofuranone

/°
3

Br

HO

@

0

c -- (|)\0
Br
Br

Br

65

OH

Bromphenol Blue: 4,4'-(3I-I-2,l,-benzoxathiol-3-ylidene)

bis[2,6-dibromophenol]S,S,-dioxide

Sulfobromophthalein sodium (BSP): 5,5'-(4,5,6,7
tetrabromo-J-oxo-l (3H)-isobenzofuranylidene)

4,25 6,727
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6

available, it must be generated from K77Br, in a manner

TABLE I-continued

such as is described by Slaunwhite and Neeley, Analyti
cal Biochemistry, Vol. 5, page 133 (1963).
The reaction vessel containing the reaction mixture is

bis[2-hydroxybenzenesulfonic acid]
disodium salt

disposed in a leaded fume hood and can be heated in any
desired manner, but it is preferred to do this by immer
sion in an oil bath maintained at the desired reaction
temperature. The heating is carried out at a temperature
and for a time period suf?cient to effect the desired
bromination reaction. The temperature may be in the
range of from about 110° C. to 125° C. Thetime of reac
tion may be in the range of from about 4 hours to 12
hours. Since HBr is formed as a by-product of the bro

Eosine I bluish: 4',5’-dibromo-3',6’-dihydroxy-Z',

7'-dinitro spiro[isobenzofuran-l(3I-I),9'[9H]xanthen]-3
one disodium salt

15

mination reaction, it is vented from the reaction vessel,

and passed serially through two NaOH containing traps

wherein it is neutralized to form NaBr. Since this is
radioactive, it can be disposed of in any suitable and
approved manner.
After the reaction has been completed, the reaction
20
vessel is flushed with nitrogen gas to remove HBr, and

the solvent is removed by evaporation. The reaction
vessel is then removed from the oil bath, preferably by
Bromlhymol Blue: 4,4'-(3H-2,l~benzoxathiol-3-ylidene)bis

[2-bromo-3-methyl-6-(l-methylethyl)phenol]S,S-dioxide

Br

CH3

the use of tongs, but maintained disposed in the leaded
fume hood. While still in the hood, the contents of the

0

reaction vessel are removed, and then subjected to a

5%0

separation procedure such as selective extraction in
order to recover the dye compound labelled with the
radioactive bromine. Thereafter, and while still being
30 maintained within the leaded fume hood, the dye com
pound is subjected to a purification procedure, e.g.,

l
I-IO

25

C - 0

CH3

column chromatography.

Br

rangement suitable for carrying out the process set forth

As stated above, FIG. 2 illustrates an apparatus ar

CH3
CH3

35 in the ?ow sheet of FIG. 1.

OI-I

Bromoxylenol Blue:

'

If 77Br2 is employed in the apparatus of FIG. 2, then

0

the 77Br2 source consists of a 77Br2 generator which
converts 77Br" to 77B1'2. This has been previously de

scribed by Slaunwhite and Neeley, utilizing manganese

O

dioxide as the oxidizing agent. The 77B1'; is distilled into
the reaction mixture and then the reaction vessel is
sealed.
The following Examples are given merely as illustra
tive of the present invention and are not to be consid
ered as limiting.

Br
0H

Bromophenol Red:

/

COZNa

Br

Br

50

\

no

\

0
Br

EXAMPLES OF THE INVENTION»
Example 1
Synthesis'of Bromphenol Blue Labelled With 77Br
Starting Material:

\o
Br

Eosine Yellowish: 2',4’,5’,7’-tetrabromo?uorescein

55

Preferably the reaction is carried out in an inert or

ganic reaction medium, such as glacial acetic acid, in
which the dye precursor compound is placed. The reac
tant bromine, i.e., 76BI‘2, 77Br2 or 82Br; , is in either the 60
gaseous or liquid state. It is preferably introduced into

HO

the reaction mixture in the gaseous state through some
kind of gas dispersing means. Introduction of the reac
tant bromine gas in this manner effects sufficient agita

tion of the reaction mixture to avoid the necessity of any
65
other kind of agitation, although this may, of course, be
done if so desired. With respect to the bromine reactant,

if 82Br; is chosen, it can be supplied directly as it is

commercially available. Since 77Br2 is not commercially

OH

The above starting compound and glacial acetic acid
were added to a reaction vessel disposed in an oil bath,

4,256,727
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all of which were placed in a leaded fume hood. There
after, 77Br; in gaseous form was supplied to the reaction
vessel. Then the reaction vessel was heated in the oil
bath at 123° C. and the reaction was completed in about
4-24 hours.
After the reaction was completed, the reaction vessel
was flushed with nitrogen gas to remove HBr, and the

8

are suitable for this purpose. Examples thereof are lactic
acid and propionic acid. In general, any acidic media in

which the brominating agent and the precursor dye are
soluble are suitable.

The flow diagram of FIG. 1 shows the reaction vessel
being heated by immersion in an oil bath. Many other
variants for such heating are available. For example, the

solvent was removed by evaporation. The reaction

reaction vessel can be jacketed, and a heat exchange
liquid circulated therethrough. An alternative is the use

vessel was then removed from the oil bath, preferably

by the use of tongs. Thereafter, and while still in the 10 of an electrically heated resistance wire wrapped
leaded fume hood, the contents of the reaction vessel
around the exterior of the reaction vessel.
were removed and selectively extracted to recover the

Next, the flow diagram of FIG. 1 teaches separation
of the dye compound from the reaction mixture by
evaporation of the reaction medium followed by selec

desired product, i.e., the dye compound labelled with
radioactive bromine, which was then puri?ed by col
umn chromotography. The product had the formula:

tive extraction. This, of course, could be varied in many

ways. For example, chromatographic techniques such
as tlc and hplc, etc., are suitable.

0

Further, the flow diagram of FIG. 1 shows puri?ca

Br

tion of the dye compound by column chromatography.

/

Other procedures such as recrystallization, etc. are also
suitable.

ISAC

HO

An alternative synthesis in which the starting mate
rial is the relatively inexpensive bromide anion (76Br—,

C —— 0

25

Br

“Br

77Br‘, or 82Br—) can be ,carried out. Speci?cally, a

solution of the alkali salt of the appropriate isotopic
bromide is added to an acidic solution of potassium

Br

bromate and the speci?c precursor dye. The resultant

OH

solution is extracted into benzene, and the extract

This‘product was diluted with an aqueous buffer, and 30 worked up in a similar fashion to that described in Ex
ample 1 for the reaction mixture containing the labelled
then stored in a lead container in the leaded fume hood
dye.
in which it had been prepared.
USE IN PATIENTS

Examples 2-1 3
The procedure set forthin Example 1 above was car 35

ried out, but employing as the starting material in each
example, the immediate precursor compound contain
ing no bromine but otherwise corresponding to the

body. Digital data can also be stored on magnetic tape,

allowing computer processing to provide graphs show
ing activity variations with time in selected areas of the

obtained by these Examples 2-13 correspond to entries

scan (liver, gallbladder, intestine, etc.).

2 to 13 in said Table I above.
45

With respect to the dyes which are labelled with
radioactive 76Br, 77Br or 82Br, this invention is not lim
ited to the speci?c dyes disclosed in the foregoing de
scription. Thus, these speci?c dyes can be modi?ed so
that the bromine substituents can be at positions other 50

than those speci?cally shown.

isotope of bromine, i.e., 76Br, 77Br or 82Br, is injected
intravenously into the patient. Following injection, the
liver and biliary system are monitored using equipment
which maps radioisotope distribution within the human

compounds listed as entries 2-13 Table I above. The
reaction temperature and time of reaction were varied
as required to obtain the desired product. The products

MODIFICATIONS AND EQUIVALENTS

'

The selected dye labelled with a gamma-emitting

Distribution studies of the labelled dye after intrave
nous injection show initial rapid clearance of the radio

activity from the blood, speci?cally by the liver, with
subsequent, almost complete, excretion into the biliary
tract. Stated otherwise, the labelled dye of this inven
tion rapidly accumulates in the liver, and then is ex
creted from the liver to the biliary tract, so as to be

useful for hepatic-biliary morphology and function

studies.
The monitoring equipment to be employed is well
known in the art. One type of monitoring equipment
shown in the foregoing description. Any known bro 55 found to be particularly useful for the purposes of this
invention is of the scanning type, i.e., the scanning head
mine-containing dye which is excreted to a large extent
thereof is caused to trace an interlaced pattern which
in the bile of a number of animal species is suitable if it
covers the area of the body which is of interest. One
is labelled with 76Br, 77Br or 32Br, i.e., if the non-radi
example of such equipment 'is that described in US. Pat.
oactive Br substituents are replaced by 76Br, 77Br or
No. 3,509,341 to Hindel et al, issued Apr. 28, 1970. In
82Br in part or in whole.
this system there is provision for storing the scanning
Finally, with respect to the dyes which are taught as
data on magnetic tape for any desired use.
labelled with radioactive 76Br, 77Br or 1'32Br, thisinven
If it is desired to use monitoring equipment of the
tion is not limited to the use of these three bromine
camera type, i.e., stationary with respect to the human
isotopes. Any gamma-emitting isotope of bromine can
be employed.
65 body, but which can be‘employed to monitor speci?c
areas of the human body, then US. Pat. No. 3,983,394
Moreover, although the flow diagram of FIG. 1
shows the reaction as being carried out in glacial acetic
to Martone et al, issued Sept. 28, 1976, is of particular
acid, there are many other inert reaction media which
interest. In this system there is provided window gener
In addition, the dyes which are labelled with radioac
tive 76Br, 77Br or 82Br and which can be prepared by
this invention are not limited to the classes of dyes

4,256,727
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ating circuitry for de?ning a window in the detector
?eld of view, and for gating to an output an indication

of only those stimuli occurring within the window. This
enables a very precise monitoring of a speci?c organ in
the human body to be carried out.
The system described in US. Pat. No. 3,308,438 to

Spergel et a1, issued Mar. 7, 1967, is of particular interest
with respect to the dynamic imaging studies referred to
above. In this system radiation data are accumulated for
a short period of time and then destructively read out of
the memory and displayed on a cathode ray tube at
selected rates. Such a system has numerous advantages,
e. g., an immediate and accurate presentation of the

XI

monitored subject may be observed, in detail as the

wherein
X1 is Br or CH3,

actual events occur, or the system may be employed to

provide permanent records ‘for subsequent study as
desired.

I’

',

. X2 is Br or CH3,v

.

X7 is Br or H, and

The [invention being .thus, described, it willbe obvious

XgiSBI‘OI'H,

that the same may be variedin many ways. Such varia
tions are not to be regarded as ‘a departure from the

'

‘

-

"'

with the proviso that X1 and X2 must be the same; with

the additional proviso that when X] and X; are Br, then

spirit and scope of the invention, and all such modi?ca

X3_6 is H, and X7 and X8 are Br or H; with the further
tions are intended to be included within the scope of the 25 proviso that when X1 and X; are CH3 , then X3_6 is H
following claims.
and X7 and X3 are Br; with the still further proviso that
What is claimed is:
when X3_6 is Br, then X1 ,X2 ,X7 and X3 are Br; and with
the final proviso that the Br substituents are gamma
1. A process for imaging the liver or biliary tract of a

patient comprising the steps of:
intravenously injecting the patient with a dye labelled
with a gamma-emitting isotope of bromine; and
then scintigraphically imaging the liver or biliary

30

emitting isotopes.
9. A process as recited in claim 8 in which the dye

labelled with a gamma-emitting isotope of bromine has
the structural formula:

tract of the patient.
2. A process as recited in claim 1 in which the gam

0

ma-emitting isotope of bromine is selected from the
group consisting of 76Br, 77Br and 82Br.
3. A process for serially imaging the liver and biliary

Br

/

s——>o

1

tract of a patient comprising the steps of:

HO

intravenously injecting the patient with a dye labelled
with a gamma-emitting isotope of bromine; and
then scintigraphically imaging the liver and biliary

C ——- 0

Br

tract to follow the movement of radioactivity into

Br

Br

the liver and then from it’ through the biliary tract.

OH

4. A process as recited in claim 4 in which the gam

ma-emitting isotope of bromine is selected from the
group consisting of 76Br, 77Br and 82Br.

in which the Br substituents are 77Br.
10. A process as recited in claim 5 in which the dye

5. A process for imaging the liver or biliary tract of a 50 labelled with a gamma-emitting isotope of bromine has
the structural formula:

patient comprising the steps of:

intravenously injecting the patient with a dye se
lected from the group consisting of triarylmethane
dyes and the phthalein subclass of the class of Xan
thene dyes, said dye being labelled with a gamma

emitting isotope of bromine; and then scintigraph
ically imaging the liver or biliary tract of the pa
tient.

X5

‘I I,

X7

X1

C

‘a’
C

OH

X6

X5
X2

6. A process as recited in claim 5 in which the gam

ma-emitting isotope of bromine is selected from the
group consisting of 76Br, 77Br and 82Br.

X4

7. A process as recited in claim 5 in which the gam

ma-emitting isotope of bromine is 77Br.
8. A process as recited in claim 5 in which the dye

labelled with a gamma-emitting isotope of bromine has
the structural formula:

X3
OH

65 wherein

X1 is Br or SO3Na,
X2 is Br or H,
X3 is Br or H,
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X4 is Br 01' SO3Na, and

X4

.

X5

X54; is Br or H,

X3
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.

.

X6

with the proviso that X] and X4 must be the same; with

X1

Br

B

\

the additional proviso that when X1 and X4 are SO3Na, 1o
.

r

\
X2

then X; and X3 are H and X5_g is Br; and with the ?nal

0

\0

Br

Br

proviso that the Br substituents are gamma-emitting 15 WESIZHCOZCHZCH3 or COzNa,
‘
isotopes.

'

X2 is OH or NaO, and

,

X3_6 is C] or H,

,

with the proviso that when X1 is CO2CH2CH3, ‘then X2
11. A process as recited in claim 5 in which the dye
_

, _

_

is OH and X3_6 is H; with the additional proviso that
20 when X1 is COzNa and X3_6 is Cl, then X; is NaO; with

,

the further proviso that when X] is COzNa and X3_6 is

labelled with a gamma-emitting lsotope of bromine has

H, then X2 is OH; and with the ?nal proviso that the B1.
substituents are gamma-emitting isotopes.
*

the structural formula: 1
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